ON
← Back to feed
NHS trials first multi-cancer blood test to investigate common symptoms often dismissed
United Kingdom🩺 Health

NHS trials first multi-cancer blood test to investigate common symptoms often dismissed

The National Health Service (NHS) in England is launching the STRIDE-RCT trial, a study designed to evaluate the effectiveness of multi-cancer blood tests for early detection. The trial will recruit 20,000 patients aged over 45 from 200 general practitioner surgeries across the country. Participants experiencing common gastrointestinal symptoms, such as bloating or heartburn, will undergo blood tests that analyze tumor-derived DNA and specific proteins using artificial intelligence. The initiative aims to address the challenge of diagnosing abdominal cancers like pancreatic, ovarian, and bowel cancer, which are frequently identified at advanced stages due to non-specific symptoms. Health Secretary Yvette Cooper stated that the trial seeks to determine if these tests can enable earlier intervention, potentially saving lives by shifting diagnoses to stages where treatment is more effective.

The National Health Service is preparing to launch a major clinical trial involving twenty thousand patients to evaluate blood tests designed to detect early signs of multiple common cancers. The study, designated STRIDE-RCT, aims to determine if these screenings can help general practitioners identify patients requiring urgent care before symptoms become severe. Government officials have backed the initiative, citing its potential to improve survival rates for diseases that are frequently misdiagnosed due to non-specific physical complaints. Participants will be recruited from two hundred GP surgeries across the country. Eligible individuals must be over the age of forty-five and present with specific gastrointestinal issues. These symptoms include bloating, stomach cramps, heartburn, diarrhea, and constipation. Such signs are often attributed to minor ailments, making early detection challenging. The trial focuses on abdominal malignancies, including prostate, ovarian, bowel, pancreatic, stomach, and liver cancers. The screening process involves collecting one or two tubes of blood during routine visits. The tests analyze DNA fragments shed by tumors along with specific proteins in the bloodstream. Artificial intelligence algorithms will process these biological markers to suggest where in the body a tumor might originate. Most of the testing technology was developed by the University of Birmingham. Three different commercial providers are participating in the evaluation. Their methods allow a single blood sample to screen for various types of cancer simultaneously. General practitioners will continue to exercise their clinical judgment throughout the trial. They will record the strength of their suspicion regarding cancer diagnoses. Researchers will compare these professional assessments with the results generated by the new blood tests. This comparison is essential to understand how effectively the technology complements traditional diagnostic practices. The goal is to ensure that the right patients receive the correct specialized tests as soon as possible. Health Secretary Yvette Cooper stated that earlier diagnosis significantly increases the likelihood of successful treatment. She described the project as a world-first effort to establish whether simple blood draws can aid GPs in identifying high-risk patients promptly. Professor Peter Johnson, the NHS England director for cancer, noted that abdominal cancers are notoriously difficult to detect early because their symptoms mimic less serious conditions. He expressed gratitude to those participating in the research, calling the period a starting point for a revolution in cancer diagnosis. Statistics highlight the urgency of the issue. Approximately seventy thousand people in England are diagnosed annually with pancreatic, stomach, liver, ovarian, or bowel cancer. Nearly thirty-five thousand deaths result from these conditions each year. Survival rates vary drastically based on the stage at discovery. About ninety percent of patients diagnosed with stage one bowel cancer survive at least five years. In contrast, only about one in ten survives if the disease reaches stage four. Business Secretary Jonathan Reynolds emphasized that finding cases early provides patients with a clear path to treatment. He asserted that the United Kingdom maintains a leading position in medical science research. The trial demonstrates how this scientific leadership translates into practical breakthroughs that benefit public health. The final decision on whether to roll out these tests nationwide depends on the trial's findings regarding accuracy and utility within primary care settings.

How this report was made. Objective News wrote this report from 2 source articles, using AI-assisted synthesis under our methodology. It is our own text, not a copy of any single outlet. Read our methodology.

Responsible editor: Matej BašaSpotted an error? Report it

2 reports

Daily Mirror logoDaily MirrorIndependentCenterFactual 85Objective 80
NHS trials first multi-cancer blood test to investigate common symptoms often dismissed

The National Health Service (NHS) in England is launching the STRIDE-RCT trial, a study designed to evaluate the effectiveness of multi-cancer blood tests for early detection. The trial will recruit 20,000 patients aged over 45 from 200 general practitioner surgeries across the country. Participants experiencing common gastrointestinal symptoms, such as bloating or heartburn, will undergo blood tests that analyze tumor-derived DNA and specific proteins using artificial intelligence. The initiative aims to address the challenge of diagnosing abdominal cancers like pancreatic, ovarian, and bowel cancer, which are frequently identified at advanced stages due to non-specific symptoms. Health Secretary Yvette Cooper stated that the trial seeks to determine if these tests can enable earlier intervention, potentially saving lives by shifting diagnoses to stages where treatment is more effective.

Bias read (Center): The article presents a straightforward report on a medical trial with balanced quotes from health officials and neutral statistical data regarding cancer survival rates.

Why factuality (85): The article provides specific details (20,000 patients, 200 GP surgeries, list of cancers) that align with typical reporting on this topic. However, the date '04 Nov 2026' appears to be a future date relative to current real-world time, suggesting either a typo in the prompt data or a fictional/futu

Why objectivity (80): The tone is generally informative but includes standard tabloid-style engagement baiting ('stories you love', 'Free and easy-to-do'). The quote from the Health Secretary uses slightly positive framing ('world-first', 'lives can be saved'), which is acceptable as direct speech but contributes to a sl

Sky News (UK) logoSky News (UK)IndependentCenterFactual: no official source document/info detectedObjective 100
Blood tests that could spot early signs of cancers to be trialled on thousands of NHS patients

A new blood test designed to detect early signs of several common types of cancer is set to undergo clinical trials involving thousands of National Health Service (NHS) patients. This initiative aims to improve early diagnosis rates for various malignancies through non-invasive screening methods. The trial represents a significant step in medical research within the UK healthcare system.

Bias read (Center): The article reports on a medical trial using neutral, factual language without political commentary or partisan framing.

Why factuality: no official source document/info detected

Why objectivity (100): The text is extremely brief and purely informational. There is no opinion, emotional language, or bias present.

How each side covered it

The same event, grouped by the political lean of the outlets covering it.

How each side covered it

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Covered around the world

The same event as reported in other countries.

Covered around the world

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Claims check

Key factual claims, and how many sources assert vs dispute each.

Claims check

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.

Become a Supporter

Related stories